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Background: Bleeding following colonoscopic polypectomy is a common complication and has been reported to
occur in up to 6.1% of patients. Several risk factors have been discussed but their overall contribution to
post-polypectomy bleeding remains controversial. The aim of the study was to determine the rate of post
polypectomy bleeding and to analyse the role of potential risk factors especially the role of aspirin.
Methods: We conducted a retrospective cohort study of all patients who underwent polypectomy at Dunedin
Hospital, New Zealand between January 2007 and June 2009.
Results: During the study period, 514 patients underwent colonoscopy with polypectomy and a total of 1502
polyps were removed. From further analysis we excluded 21 patients; 15 patients had surgery immediately after
colonoscopy for the diagnosis of colorectal carcinoma and 6 patients presented with symptoms of an acute lower
gastrointestinal bleed prior to colonoscopy. Of the remaining 493 patients, 11 patients (2.2%) presented with
post-polypectomy bleeding within 30 days of the investigation of which 8 were on aspirin. In total 145 patients
were taking aspirin prior to colonoscopy and 348 patients were not taking aspirin. The use of aspirin was associated
with an increased prevalence of post-polypectomy bleeding (OR=6.72, 95% C.I. 1.76 to 25.7). Interestingly, the use
of non-steroidal anti-inflammatory drugs (NSAIDs) was not associated with risk of bleeding after polypectomy
(OR=2.82, 95% C.I, 0.34 to 23.3).
Conclusion: Our study confirmed a significantly increased risk of lower gastrointestinal bleeding following
polypectomy in patients taking aspirin. We would recommend approaching the patient on aspirin coming forward
for a colonoscopy with potential polypectomy with caution.
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Colonoscopic colon cancer screening programs are
being adopted world-wide. As a consequence, more
patients undergo colonoscopy with polypectomy. Bleed-
ing is a common complication that has been reported in
approximately 0.2 – 6.1% of patients undergoing endo-
scopic polypectomy [1-3].
Aspirin is widely used for secondary prevention of
myocardial infarction, stroke, and vascular death among
patients who have survived an initial occlusive cardio-
vascular disease event [4-6]. In the UK, aspirin is used
by 67% of the general population older than 35 years of* Correspondence: michael.schultz@otago.ac.nz
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reproduction in any medium, provided the orage following a cardiovascular event but also by 7% in
those without a cardiovascular event [5]. In New Zea-
land, at least 54% of the elderly population in residential
care is using aspirin for secondary cardiovascular risk
reduction [6].This has raised a management issue for
patients on aspirin undergoing diagnostic and thera-
peutic endoscopy, as aspirin can prolong bleeding time
after endoscopic biopsy and polypectomy [7,8]. The
most recent European Society of Gastrointestinal En-
doscopy (ESGE) Guideline published in 2011 recom-
mends that aspirin does not need to be discontinued
even before planned polypectomy [9]. The aim of our
study was to retrospectively determine the rate of
bleeding following colonoscopic polypectomy and to
analyse the role of risk factors especially aspirin in this
setting.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study Population
Dunedin Hospital is the only secondary/tertiary hospital
in the region, providing colonoscopic services to a popu-
lation of approximately 193,803 [10]. Consecutive
patients who underwent colonoscopic polypectomy be-
tween January 2007 and June 2009 at Dunedin Hospital,
Dunedin, New Zealand were identified retrospectively
from the endoscopy reporting database (EndoSmart,
Dunedin, New Zealand). Retrospectively, each patients’
colonoscopy report was reviewed for polyp characteris-
tics (sessile, semi-sessile, on a stalk), polyp size, method
of polypectomy (cautery snare, hot or cold forceps), and
number of polyps removed was recorded. The patients’
medical records were reviewed for demographical data,
the indications for colonoscopy, use of NSAIDs, anti-
coagulant or antiplatelet agents and the prevalence of
bleeding following polypectomy. A retrospective review
of each patient’s clinical records, hospital files and elec-
tronic records was performed to establish the use of
medications both prior to and post procedure. These
records include general practitioners referral letter, nurse
notes, and physicians’ inpatient and outpatient record.
Patients on anticoagulants follow a standardized
protocol in our unit. Patients with current warfarin use
for valvular heart disease are switched to enoxaparin 5
days prior colonoscopy and instructed to omit the enox-
aparin dose on the morning of the procedure. PatientsFigure 1 Methodology flow chart.on warfarin for atrial fibrillation are instructed to stop war-
farin 5 days prior procedure. Patient with elevated inter-
national normalized ratio (INR) greater than 1.5 are
rescheduled. Patients on intravenous heparin are instructed
to stop infusion 6 hours prior the procedure. Patients tak-
ing aspirin and NSAIDs are not told to discontinue the
medication prior to procedure.
Patients’ medical records were used to identify any clinic-
ally important delayed post-polypectomy bleeding requiring
attendance to hospital. Clinically important delayed post-
polypectomy bleeding was defined as lower GI bleeding
requiring transfusion, hospitalization, re-intervention or
surgery within 30 days of the procedure. Patients who
developed mild and self-limiting hematochezia after poly-
pectomy and not requiring re-admission were not included.
Dunedin Hospital is the only secondary/tertiary hospital in
the region, and all regional hospitals share the same com-
puter inpatient management system. Therefore, all patients
who developed significant post-polypectomy bleeding
requiring hospital admission were included in the study.
Patients were excluded if the procedure was performed
primarily for acute upper or lower gastrointestinal bleed-
ing. Patients who underwent surgery within 30 days after
the procedure for reasons other than bleeding (e.g. colo-
rectal carcinoma) were also excluded (Figure 1).
Statistical significance was assessed by determining the
odds ratio (OR) from a conditional logistic model for
matched pairs and 95% confidence interval (CI) around
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approved by Lower South Regional Ethics Committee,
New Zealand.
Results
A retrospective cohort study was conducted on all
patients who underwent endoscopic polypectomy at
Dunedin Hospital, New Zealand, between January 2007
and June 2009. During the study period, a total of over
1500 colonoscopies were performed. 514 patients under-
went colonoscopy with polypectomy of which 21
patients were excluded (Figure 1). Of these, 15 patients
had surgery immediately after colonoscopy for colonic
or rectal carcinoma and 6 patients had presented with
symptoms of acute lower GI bleed before colonoscopy.
The most common indications for colonoscopy were
iron-deficiency anemia, hematochezia, positive faecal oc-
cult blood, history of polyps, screening for colorectal
cancer, and changing bowel habit.
A total of 1502 polyps were removed from the
remaining 493 patients, 314 (63.4%) colonoscopies were
for symptom assessment and 181 (36.6%) were for sur-
veillance and screening. 145 patients were taking aspirin
prior to colonoscopy and 348 patients were not taking
aspirin.
Our two study populations (aspirin vs non aspirin)
were significantly different (p<0.05) regarding the aver-
age age (Table 1) but there were no significant differ-
ences in gender, concomitant NSAID and dipyridamole
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Number of patients presented with post-polypectomy bleed450 polypectomies were performed in the aspirin
group and a total of 1052 in the non-aspirin group. The
greatest number of polyps removed in a patient on as-
pirin was 30; the largest polyp removed was 40 mm. In
the non-aspirin group the greatest number of polyps
removed in a patient was 26; the largest was 60mm.
There were no significant differences between two
groups in regards to number of polypectomies per pa-
tient and average of polyp size per patient. The majority
of polyps were removed by cautery snare using blended
current with 63.4% in the aspirin group and 59.5% in the
non-aspirin group. There was no difference between the
two groups for use of different polypectomy techniques.
Eleven patients (2.2%) presented with post-
polypectomy bleeding within 30 days post the procedure.
Eight of the 11 patients were taking aspirin prior to col-
onoscopy compared to three patients who were not tak-
ing aspirin (Table 1). The use of aspirin was associated
with a significantly increased prevalence of post-
polypectomy bleeding (OR=6.72, 95% C.I. 1.76 to 25.7).
The average age of patients in the aspirin group who
experienced post-polypectomy bleeding was 72.1 com-
pares to 62.2 in the non-aspirin group, however, there
was no statistical significant difference between two
groups. There was also no difference between the two
groups regarding average polyp size (p=0.66), average
number of polyps removed per patient (p=0.62), gender
(p= 0.35), polypectomy technique (p=0.17) and concomi-
tant use of NSAIDs and/or dipyridamole. The average
days of admission for patients on aspirin presenting withspirin group Non-Aspirin group p value
145 348
72.1 (0.7) 62.2 (0.7) p<0.05
83 (57.2%) 191 (54.9%) NS, p=0.63
4 (2.8%) 12 (3.5%) NS, p=0.68
2 (1.4%) 3 (0.9%) NS, p=0.64
450 1052
1-30 1-26
3.1 (0.3) 3.1 (0.5) NS, p=0.79
2-40 mm 2-60mm
.6 (0.7) mm 9.2 (0.5) mm NS, p=0.59
35 (24.1%) 90 (25.9%) NS, p=0.69
18 (12.4%) 51 (14.7%) NS, p=0.50
92 (63.4%) 207 (59.5%) NS, p=0.43
8 (5.5%) 3 (0.8%) p<0.05
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days in patients not on aspirin. In the aspirin group, one
patient required multiple transfusions, emergency sur-
gery and long (22 days) hospitalisation. There was one
death directly related to post-polypectomy bleeding. Of
the remaining 6 patients, 5 required blood transfusions
and one patient was treated conservatively. In the non-
aspirin group, 2 patients were managed conservatively
(observation only) and 1 patient required endoscopic
therapy. There was no death in the non-aspirin group
(Table 2).
A further 16 patients were taking NSAIDs prior to col-
onoscopy of which one presented with post-
polypectomy bleeding. In contrast to aspirin, the use of
NSAIDs was not associated with an increased risk of
bleeding after polypectomy (OR=2.82, 95% C.I, 0.34 to
23.3).Discussion
Post-polypectomy bleeding (PPB) is a common compli-
cation that has been reported in up to 6.1% of patients
[1-3]. Although in general, the prognosis for PPB is
favourable, management of these patients can be
costly, including hospitalization, blood transfusion and
possible further endoscopic intervention. A small pro-
portion of patients will require surgery or angiographic
haemostasis.
Aspirin is widely used as secondary prophylaxis for
cardiovascular events and has been shown to prolong
colonic bleeding time after endoscopic biopsy and poly-
pectomy [7,8]. The safety of polypectomy in patients tak-
ing aspirin is controversial. Our study retrospectively
analysed post-polypectomy bleeding events in 493







Cautery snare (blended current) 6 3
Hot biopsy 2 0
Preventive clips placement 0 1
Preventive adrenalin injection 1 0
Average length of
hospitalization (range)







Death 1 0associated with a significantly increased risk of post-
polypectomy bleeding (OR=6.72, 95% C.I. 1.76 to 25.7)
and the average length of hospitalisation in patient with
bleeding was significant longer in the aspirin group.
No other factors including the use of NSAIDs prior to
colonoscopy, polyp characteristics and method of poly-
pectomy were associated with an increased risk of post-
polypectomy bleeding.
A review of published studies on the use of aspirin in
patients undergoing polypectomy demonstrates a wide
variation. A published survey of members of the Ameri-
can Society of Gastrointestinal Endoscopy (ASGE)
revealed that 81% of responders would consider discon-
tinuation of aspirin before colonoscopy and 61% would
not perform snare polypectomy in patients on aspirin
[11]. In 1994, Shiffman et al. published a prospective
study of 694 patients and found a small (<1%) increase
in the risk of post-polypectomy bleeding in patients tak-
ing aspirin or NSAIDs [12]. Hui et al. [13] published a
retrospective study involving 1657 patients who under-
went colonoscopy with polypectomy, and concluded that
the use of aspirin and NSAIDs was not associated with a
higher risk of polypectomy-associated bleeding. A case-
controlled study published by Yousfi et al. [14] also con-
cluded that polypectomy can be safely performed in
patients taking aspirin. Based on these studies a number
of guidelines have been published, the ASGE guideline
(2009) on the management of anticoagulation and anti-
platelet therapy for endoscopic procedures suggests that
aspirin and other NSAIDs in standard dosages do not
increase the risk of significant bleeding after gastroscopy
with biopsy, colonoscopy with biopsy, polypectomy or
biliary sphincterotomy. The guideline recommends fur-
ther that aspirin may be continued for all endoscopic
procedures. However, when high risk procedures, includ-
ing polypectomy, are planned, the individual clinician
may elect to discontinue aspirin for 5 to 7 days before
the procedure depending on the underlying indication
for antiplatelet therapy [15]. This recommendation is in
contrast to the recent European Society of Gastrointes-
tinal Endoscopy (ESGE) guideline which recommends
that aspirin does not need to be discontinued even be-
fore planned polypectomy irrespective of the polyp size
[8]. A published survey in 2008 showed significant dif-
ference between Eastern and Western endoscopists in
the management of antiplatelet medications before
endoscopic procedure [16]. The Japanese Gastroentero-
logical Endoscopy Society guideline recommends stop-
ping aspirin before any endoscopic procedure, even if
the procedure is considered low risk [16,17].
The use of aspirin for primary prevention remains
controversial. Aspirin did not reduce the occurrence of
stroke or “all cardiovascular events” compared to pla-
cebo in primary prevention patients with elevated blood
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Cochrane collaboration group concluded that the mag-
nitude of harm is similar to the benefit, therefore aspirin
cannot be recommended for primary prevention in
patients with elevated blood pressure [18]. However, as-
pirin is established as an effective agent for secondary
prevention in patients with proven cardiovascular dis-
ease [4]. Study [19] showed coronary events occurring
after aspirin withdrawal represents 13.3% of coronary re-
currence. Temporary withdrawal of oral antiplatelet
agents is associated with increased risk of 30-days myo-
cardial infarction and death [20]. Most of the patients
with known heart disease are over 50 years of age and,
therefore, in the group of patients where colonoscopy is
required as screening and diagnostic procedure. We rec-
ommend approaching the patient who is on aspirin as
secondary prevention coming forward for a colonoscopy
with potential polypectomy with caution.
Our study has a number of limitations, most notably
its retrospective nature and single center design. Our
patients are not routinely contacted by our department
after colonoscopy unless there is abnormal finding on
the colonoscopy and therefore minor bleeding following
polypectomy, not requiring hospital attendance was
not captured. Our center shares the same electronic
inpatient management system with regional hospitals,
therefore all patients who presented with significant
delayed post-polypectomy bleeding requiring hospital-
ization were identified for this study. Another possible
limitation is the reliability of the recall history of as-
pirin use. To minimize this bias all available clinical
records including pre- and post- procedural clinical
letters, colonoscopy reports, nursing records and GP
referral letter were checked to ensure the accuracy of
medication use. We did not explore the temporal asso-
ciation and dosage of aspirin exposure with the risk of
bleeding. Nor did we take the possibility of comorbid
medical conditions which may increase the risk for
post-polypectomy bleeding into account [21,22]. The
average age of patients in aspirin group was signifi-
cantly higher than for patients in the non-aspirin
group. A possibly higher number of comorbidities
might have contributed to the higher rate of post-
polypectomy bleeding in the aspirin group. Other studies
have identified advanced age as a significant predisposing
factor for post-polyepectomy bleeding [23,24].
Conclusion
In summary according to our results, the use of aspirin
prior to colonoscopy is associated with a significantly
increased risk of lower gastrointestinal bleeding follow-
ing endoscopic polypectomy. Based on the limited bene-
fit of aspirin as primary prevention we recommend to
stop aspirin 5 to 7 days prior to planned polypectomy.Most of the patients with known heart disease are over
50 years of age and therefore in the group of patients
where colonoscopy is required as a screening and diag-
nostic procedure. We recommend approaching the pa-
tient who is on aspirin as secondary prevention coming
forward for a colonoscopy with potential polypectomy
with caution.
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